Alzheimer's drug that can slow disease gets backing from FDA advisers

A closely watched Alzheimer’s drug from Eli Lilly, donanemab, won unanimous backing from FDA advisers on Monday for its ability to slow mild dementia despite risks such as brain swelling and bleeding, setting the stage for its expected approval later this year.

Study: Salty diet may increase risk of dry, itchy skin

A new study from UC San Francisco, published in JAMA Dermatology, found that consuming just an extra gram of sodium daily can increase the likelihood of an eczema flare by 22%, with high sodium intake significantly impacting those prone to eczema.